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We have tested the hypothesis that phenotypic changes of development are accompanied  by expression 
of differentiation-stage specific peptides bound  to  major  histocompatibility  complex  (MHC) 
class I molecules. The U937 cell line, when cultured in the presence of phorbol myristate acetate 
(PMA), undergoes differentiation from monoblasts to macrophage-like cells. The high-performance 
liquid chromatography profile of peptides ehted from purified human histocompatibility leukocyte 
antigen class I molecules expressed by U937 treated with PMA differs from that obtained from 
control, untreated U937 cells. Chemical sequencing of eluted peptides identified a peptide derived 
from cytomegalovirus in both treated and untreated cells. PMA-treated, but not untreated cells, 
displayed an additional  peptide derived from interleukin 1~. Hence, differentiation-induction 
of U937 is accompanied by the presentation  of at least one differentiation-stage specific peptide. 
Our results indicate that, similar to viral infection,  cellular development and transformation is 
accompanied by the de novo synthesis of proteins which are processed and presented on MHC 
class I molecules. 
M 
HC class I molecules present peptides,  derived from 
the processing of intracellular proteins, which are sur- 
veyed by CTLs. Under normal conditions, endogenous self 
peptides presented by MHC class I molecules do not elicit 
CTL activation  (1, 2). 
Self peptides bound to MHC class I molecules have been 
partially characterized and have the following common fea- 
tures: (a) they are 8-9 amino acids in length (3, 4); (b) they 
have allele-specific structural motifs (5); and (c) although ex- 
tremely heterogeneous, they derive predominantly from a small 
set of abundantly expressed intracellular proteins (3, 4). After 
viral infection,  and perhaps  transformation,  newly synthe- 
sized viral and cellular proteins  are degraded into peptides 
in the cytosol, and transported across membranes, into a com- 
partment where they become bound to MHC class I mole- 
cules. These complexes are transported to the surface, ren- 
dering the cell susceptible to recognition and lysis by specific 
CTLs (6). 
Characterization of peptides eluted from MHC class I mol- 
ecules, after infection by vesicular stomatitis or influenza virus, 
has demonstrated that viral protein-derived peptides become 
bound to class I as viral replication  takes over the normal 
cellular protein biosynthesis (7, 8). Changes in MHC class 
I-bound peptides which might occur during cellular differen- 
tiation and/or transformation, however, have not yet been 
characterized. The identification of MHC class I-bound pep- 
tides associated with specific  phases of cellular differentiation 
and/or transformation  would not only further our under- 
standing of the antigenic nature of self, but is also a step to- 
wards identifying possible transformation-specific antigens. 
To establish whether the set of peptides bound to MHC 
class I molecules at different stages of cellular differentiation 
differs, we have used the human monocytic leukemia cell line 
U937 (9). The phenotype of U937 resembles that of mono- 
blasts. This line is able to form solid tumors in nude mice 
(10). A unique characteristic of U937 is its reversible matura- 
tion block.  Culture of these cells in the presence of PMA 
induces a wide variety of phenotypic changes  (11). These 
changes include the loss of proliferative potential and the ac- 
quisition  of many effector functions that are characteristic 
for activated macrophages, such as antibody-dependent cel- 
lular cytotoxicity, respiratory burst, and augmented release 
of IL-1. Because of the phenotypic difference between PMA- 
treated and untreated U937, this cell line provides an ideal 
model for studying changes in MHC class I-bound peptides 
occurring during differentiation. We have purified HLA class 
I bound-peptides from U937 cells at two different stages of 
differentiation,  i.e.,  as  monoblasts  and  as  PMA-induced 
macrophage-like cells. The HPLC signatures of peptides eluted 
from class I molecules obtained from untreated and PMA- 
treated  cells were different.  Sequential Edman degradation 
of peptidic material contained within HPLC peaks yielded 
two sequences that matched to CMV and IL-1B precursor 
proteins,  respectively. 
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Cell Lines and Culture Conditions.  The U937 cell line was ob- 
tained from the American Type Culture Collection ([ATCC] Rock- 
ville, MD). Cells were cultured in roller bottles using RPMI 1640 
media supplemented with 10% FCS, 1% glutamine, and 0.5% gen- 
tamycin (all from Gibco, Grand Island,  NY), at an initial density 
of 0.5  x  1@ cells/ml.  U937 cells were differentiation induced for 
96 h in fresh culture media containing 2 ng/ml PMA (Sigma Im- 
munochemicals,  St. Louis, MO). Cell viability after differentiation- 
induction was >95%. The routine hybridoma producing the mAb 
W6/32 (12) was obtained from ATCC and cultured in IgG-free 
media. 
HLA Class I Typing.  The HLA class I phenotype ofU937 cells 
was determined serologically by complement-dependent cytotox- 
icity using a pand of alloantisera  and mAbs obtained from One 
Lambda,  Inc.  (Canoga Park,  CA) as previously described  (13). 
lmmunofluorescence Cytofluorometry.  The expression  of A  and 
B locus molecules was determined, as previously described, by im- 
munofluorescence flow cytometry (14, 15) using mAbs specific for 
HLA-A3 (GAP.A3) and HLA-Bw6 (SFR8.B6), both obtained from 
ATCC. The expression of HLA-B18 was ascertained using the HLA- 
B18 specific alloantiserum  (COL. 5233) (14). 
Reagents.  The mAb W6/32 was obtained from culture super- 
natants and purified by protein A affinity chromatography with 
reagents supplied by Bio-Rad (Richmond, CA). Cyanogen bromide- 
activated Sepharose-4B, purified normal mouse IgG, aprotiuin, tosyl 
lysyl chloromethyl ketone (TICK), 1 tosyl prolyl chloromethyl ke- 
tone (TPCK), and iodoacetamide were obtained from Sigma Im- 
munochemicals, pepstatin A, leupeptin, and PMSF were obtained 
from Boehringer Mannheim (San Diego, CA). All HPLC solvents, 
TFA, NP-40, and the bicinchonnic acid (BCA) protein assay kit 
were obtained from Pierce  (Rockford, IL). Tran 3sS-label, 1,000 
Ci/mmol,  and [3H]TdR. was  obtained from ICN Biochemicals, 
Inc. (Costa Mesa, CA). All other reagents were of the highest com- 
mercially available quality. 
Assays of Di.fferentiation Induction.  Biochemical assays for the ex- 
pression of lysozyme, acid and alkaline phosphatase,  and quantita- 
tion of [3H]TdR incorporation for measuring proliferation, were 
performed as previously described (16, 17). 
lmmunoprecipitation Analysis  of Class I Expression.  U937 cells 
(5.0  x  106) were cultured in the presence or absence of PMA (2 
ng/ml) for 96 h. During the last  12 h of culture, the complete 
RPMI 1640 medium was rephced with methiouine-free R,  PMI 1640 
supplemented with 5% dialyzed FCS and 100/zCi [~SS]methio- 
nine-[35S]cysteine (Tran 3sS-label). 1~I cell surface labeling was per- 
formed as previously described  (18). Cells  (5  ￿  106) were har- 
vested, washed once in PBS, and lysed in 5 ml of cold lysis buffer 
(10 mM Tris, pH 7.8,  150 mM NaC1,  1.0%  (wt/vol) NP-40, 2 
mM EDTA, 2 mM PMSF). All subsequent steps were carried out 
at 4~  The lysates were incubated for 15 min, then centrifuged 
for 5 rain at 15,000 g. The lysates were precleared for 1 h each 
in ethanolamine-Sepharose-4B,  followed by normal mouse IgG cou- 
pled to Sepharose-4B.  HLA Class I molecules were immunopre- 
cipitated from the lysate for I h using an excess (60 #g) of W6/32 
mAb coupled to Sepharose-4B. The immunoprecipitate was washed 
in 30 vol lysis buffer, 30 vol lysis buffer supplemented to 500 mM 
1 Abbreviations  used in this  paper: BCA, bicinchonnic  acid; ER., endoplasmic 
reticulum; IE, immediate early; LA, late antigen; MCF, mean channel 
fluorescence;  lrrH, phenyhhiohydantoin;  TLCK, tosyl lysyl  chloromethyl- 
ketone; TPCK, tosyl prolyl chloromethylketone. 
NaC1, 30 vol lysis buffer, and 20 vol 10 mM Tris-HC1,  pH 7.8. 
Class I molecules were eluted from mAb-Sepharose by incubation 
for 5 min at 95~  in Laemmli sample buffer with B-ME. The 
samples were then analyzed by SDS-PAGE on a 17.5% gel. The 
gel was dried and an autoradiogram prepared after overnight ex- 
posure at  -70~ 
Immunoaflinity Purification of Class I Molecules and Ehtion of  Bound 
Peptides.  U937 cells were cultured to a final yield of 10  l~ cells in 
the presence or absence of PMA (2 ng/ml). PMA-treated cells be- 
came adherent to the roller bottle surface and were harvested in 
cold PBS containing 2 mM PMSF by gentle scraping.  Cells were 
pelleted and lysed in 150 ml lysis buffer containing the following: 
2 mM PMSF, 5 #g/ml aprotinin, 1/xM pepstatin, 1/~M leupeptin, 
20 #g/ml TPCK, 20/~g/ml TICK. All subsequent steps were per- 
formed at 4~  Lysates  were incubated on ice for 30 rain, centrifuged 
for 1 h at 28,000g, and filtered through a 0.22-/~ nylon filter. The 
filtered  lysates  were incubated with  10 ml ethanolamine-Seph- 
arose-4B for 2 h, and then with 5 ml normal mouse IgG (30 mg) 
coupted to Sepharose-4B for 2 h. The precleared lysate was diluted 
to 200 ml with lysis buffer and incubated with W6/32 (25 rag) 
coupled to Sepharose-4B for 6 h. The immunoprecipitate  was washed 
in 40 vol lysis buffer supplemented to 500 mM NaC1, 40 vol lysis 
buffer, and 20 vol 10 mM Tris-HC1, 0.5% octylglucoside, pH 7.8. 
HLA class I  molecules were eluted from mAb-Sepharose by a 
method adapted from Falk et al. (5), in three 5-ml washes, 15 min 
each, with 0.1% TFA. The washes were pooled and lyophilized. 
The lyophilized material was resuspended in 1 ml of an aqueous 
solution of 0.1% TFA (vol/vol) and the protein concentration de- 
termined by BCA assay. Aliquots containing 1 #g of protein were 
analyzed by SDS-PAGE and silver staining.  The final yields of class 
I molecules were 212 and 184 #g, from the untreated and PMA- 
treated cells, respectively. Equal masses of protein (180/~g) from 
each of the eluates were incubated for 3 min at 100~  then cen- 
trifuged through a 10,000-dalton ultrafiltration cartridge (Centricon 
10; Amicon, Danvers, MA). The low molecular weight (<10,000 
dalton) fraction was lyophilized and stored at  -70~ 
HPLC Purification and Sequencing of Eluted Peptides.  The pep- 
tide fraction was  analyzed by reverse-phase  HPLC using a C18 
column (Vydac, Hesperia, CA; 2.1  x  250 mm) and Waters As- 
sociates (Waltham, MA) equipment. The gradient was created using 
a solution (A) of H20/0.1% TFA in combination with solution 
(B) of acetonitrile/0.1% TFA at a flow rate of 0.250 ml/min. The 
low molecular weight fraction was reconstituted in solution A and 
applied to the column, l-rain fractions were collected from a linear 
1-h gradient running from 5-60%  solution B. From the absor- 
bance trace at 215 nm of the eluate, the single fractions containing 
a given peak were selected for microsequencing by NH2-terminal 
Edman degradation using a protein sequencer  (model 477A; Ap- 
plied Biosystems,  Inc., Foster City, CA). 
PCR Analysis of lL-L8 Gene Expression and CMV Infection.  Ex- 
pression of Ibl~ was determined by reverse PCR. Total R.NA was 
obtained from PMA treated (as described above) and untreated U937 
cells and reverse-transcribed  into cDNA. The cDNAs were ana- 
lyzed for the presence of 3-actin and IL-1B message using specific 
primers in the presence of [3zP]dCTP in a PCR using the condi- 
tions described by the manufacturer (Clontech, palo Alto). Amplifi- 
cation products were analyzed by agarose gel electrophoresis and 
autoradiography. The incorporated cpm were determined by scin- 
tillation counting. PCIL analysis of CMV immediate early (IE) and 
late antigen (LA) gene products were performed as previously de- 
scribed  (19). 
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Differentiation-Induction ofU937 Cells.  The phenotype of 
uninduced U937 cells resembles monoblasts. U937 cells grow 
in suspension, express low levels  of Fc receptor and chemotactic 
peptide receptor,  and lack or express low amounts of many 
of the lysosomal enzymes present in monocytes and macro- 
phages. After incubation with PMA, and a variety of other 
inducing agents, U937 cells are induced towards macrophage- 
like differentiation which is characterized  by adherence, loss 
of proliferative potential, upregulated or de novo expression 
of a variety of cell surface antigens, and the acquisition of 
microbiocidal activity (11). To document that PMA treat- 
ment of U937 cells induces differentiation, we first assayed 
the proliferative potential of PMA-treated and untreated cells 
by [3H]TdR incorporation. PMA-treated U937 cells incor- 
porated <1%  of the amount of [3H]TdR  incorporated by 
untreated cells, demonstrating inhibition of proliferation. De- 
termination of the levels of three lysosomal enzymes showed 
that PMA treatment induced increased expression of acid phos- 
phatase,  alkaline phosphatase, and lysozyme, all consistent 
with a macrophage-like phenotype (16) (Table 1). 
Expression of HLA  Class I  Molecules after l~'fferentiation- 
Induction.  Malignant transformation is often accompanied 
by changes in the level of MHC class I expression (20). Such 
changes may result in quantitative and/or qualitative  differ- 
ences between peptides bound to the MHC molecules ex- 
pressed by normal and malignant cells. Hence, we determined 
whether differentiation-induction of U937 cells affects the 
expression of class I molecules. We first compared the total 
amounts of class I molecules in PMA-treated and untreated 
cells by metabolic labeling and immunoprecipitation  of HLA 
class I molecules with mAb W6/32. The mAb W6/32 recog- 
nizes  all mature HLA-A, B,  and C  heavy chain-B2-micro- 
globulin heterodimers (21). We found that the total amount 
of class I expressed did not change after differentiation in- 
duction by PMA treatment (Fig.  1). This observation was 
corroborated by cell surface labeling of 106 cells with 12sI and 
immunoprecipitation of HLA class I molecules with mAb 
W6/32. Bands of equal intensity were obtained from PMA- 
treated and untreated cells (data  not shown). 
Table  1.  PMA-induced Differentiation of U937  Cells 
Control  PMA  (2  ng/ml) 
Adherence*  <5%  >90% 
[3FI]TdR. incorporation  98,631  cpm*  271  cpm 
Acid phosphatase  3.0  Us  8.0  U 
Alkaline phosphatase  24.0  U  60.0  U 
Lysozyme  5.2  U  11.2  U 
* U937 cells normally grow in suspension.  After differentiation induc- 
tion cells become adherent to substratum. 
Mean cpm, 5  x  103 cells from triplicate cultures. 
S 1 U  equals  A  absorbance  x  103/5  min/10  s cells. 
Figure  1.  Expression of HLA class I molecules by differentiation-induced 
and uninduced U937 cells. PMA-treated and untreated U937 calls were 
metabolically labeled with [3sS]methionine. Detergent lysates of labeled 
cells were immunoprecipitated with mAb W6/32. The immunoprecipi- 
tare was analyzed by SDS-PAGE on a 17.5%  acrylamide gel and prepared 
for autoradiography.  The autoradiogram is from an overnight exposure 
at  - 70~ 
To determine whether the relative amounts of HLA-A and 
HLA-B locus proteins change after differentiation-induction, 
we analyzed the level of expression of the individual HLA-A 
and -B antigens by immunofluorescence  flow cytometry. The 
HLA class I phenotype of U937 is HLA-A3, B5(51), B18, 
Cwl, Cw7, Bw4, Bw6. Testing of the cells with HLA-A3 
and Bw6 specific mAbs, and with an alloantiserum specific 
for HLA-B18, showed that the mean channel of fluorescence 
(MCF) remained unchanged after PMA induction of U937 
cells (Fig. 2). This indicates that differentiation induction of 
U937 did not alter the expression of HLA class I molecules. 
Comparison of  HLA Class I Bound Peptides  from Normal and 
Differentiation-Induced U937 Cells.  To determine whether the 
set of MHC class I bound peptides expressed by transformed 
monoblastic cells differs from that displayed by differentia- 
tion induced more mature (i.e., macrophage-like)  U937 cells, 
we purified MHC class I bound peptides from PMA-treated 
and untreated U937 cells. 
MHC class I molecules were purified by immunoa~nity 
chromatography from U937 monoblasts and macrophage- 
like cells (Fig. 3). Peptides, bound to equal masses of MHC 
class I molecules, were released by denaturation and purified 
by ultrafiltration and reverse-phase HPLC. Several absorbance 
peaks at 215 nm were observed in the peptide pools obtained 
from PMAotreated and untreated cells (Fig. 4). Most peaks 
were common to PMA-treated and untreated cells (peaks 1-4), 
though in certain instances quantitative differences could be 
seen (peaks  1 and 2).  Some peaks, eluting between 30 and 
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Figure 2.  Cell surface expression of HLA-A3, Bw6, and BI8 molecules 
on differentiation-induced  and uninduced U937 cells. PMA-treated and 
untreated U937 cells were reacted with aUele-specific  mAbs or alloantisera 
followed by FITC-labded anti-mouse or anti-human Ig. The fluorescence 
intensity (mean channel of fluorescence) of the cell populations was mea- 
sured  by flow cytometry. (  ..... ) Uninduced U937. (  ........  ) Differentiation- 
induced U937. (,4) HLA class I expression using mAb W632 (reacts with 
all HLA A, B, and C  molecules). (B) HLA-A3 expression using mAb 
GAP.A3. (C) HLA Bw6 (an epitope of HLA-B51) expression using mAb 
SFR.8.B6. (D) HLA-B18 expression using Col 5322 alloantiserum. 
35 min, appeared to be unique to untreated cells, yet no se- 
quence information could be obtained from them. Eight HPLC 
fractions eluting between 16 and 29 min were submitted for 
sequential NH2-terminal Edman degradation.  One of these 
fractions, peak 2 from non PMA-treated U937,  gave no se- 
quence information. Full confidence sequence information 
of peptides  were obtained  from three fractions of the non 
PMA-treated group (peaks 1, 3, and 4) and from four frac- 
tions of the PMA-treated group (peaks 1-4).  We were able 
to match two of the sequences to their known precursors. 
The approximate  yields of each of the sequenced peptides 
are shown in Table 2. 
From peak 1 we obtained the amino acid sequence SEY- 
Figure 3.  SDS-PAGE  analysis  of HLA 
class I molecules  purified from U937 cells. 
HLA class I molecules were purified by 
immunoaffnity chromatography  using 
the mAb W6/32 from detergent lysates 
of 101~  cells. HLA class I molecules were 
eluted from the affinity matrix in dilute 
TFA and a 1-/~g aliquot was analyzed by 
SDS-PAGE  on a 17.5% acrylamide  gel fol- 
lowed by silver staining. 
e~  1 
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Figure 4.  Reverse  phase HPLC separation of MHC class I bound pep- 
tides, isolated from U937 cells. (~p) U937 cells. (Bottom)  Differentiation- 
induced (PMA-treated) U937. HLA class I molecules were purified by im- 
munoaffnity chromatography. Peptides bound to class I were released by 
heat denaturation in dilute TFA, and purified by ultraf~tration.  Peptide 
mixture was separated on a C18 column (250  x  2.1 ram) using a 5-60% 
acetonitrih (0.1% TFA vol/vol) gradient run over 1 h at a flow rate of 
0.25 ml/min. 1-min fractions were collected. 
Table  2.  HLA Class I Bound Peptides Isolated  from  U937 Cells 
Peak  U937  Yield  Sequence  Precursor 
pmol 
1  PMA  6.11"  SEYRVKEYKt  CMV 
1  Non-treated  3.45  SEYRVKEYK 
2  PMA  3.57  SVDPKNYPK  IL-1/~ 
2  Non-treated  <0.30 
2  PMA  0.56  ALYGVAA  Unknown 
2  Non-treated  <0.3 
3  PMA  2.13  KVYPSXAS  Unknown 
3  Non-treated  2.82  KVYPSXAS 
4  PMA  3.56  XIXKVGNQK  Unknown 
4  Non-treated  4.18  AVPASXKV  Unknown 
* Yield of first PTH-amino acid derivative of the sequence. 
Standard  IUPAC amino acid  abbreviations  are used.  X  denotes  an 
unidentifiable PTH-amino acid derivative. 
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banks matched this sequence to HXLF1, a predicted trans- 
membrane glycoprotein coded in the short unique sequence 
region of the CMV strain AD169 genome (10). The data 
base sequence, SEYRVEYSE, matches the identified peptide 
at seven out of nine residues (SEVRV-E-Y). By comparison 
to a standard phenylthiohydantoin  (trrH) amino acid deriva- 
tive, the estimated yield of the CMV peptide obtained from 
induced calls was 6.11 pmol. Uninduced cells yielded 3.45 
pmol of this peptide. Since the total amount of HLA class 
I molecules from which the pool of peptides was obtained 
was  •4,000  pmols, it  appears  that  this peptide occupied 
'~0.1% of the HLA class I binding site. This is a conserva- 
tive estimate, however, since it is based on all the MHC class 
I molecules expressed by U937 cells, rather than on the specific 
allelic product to which the peptide was bound. 
In peak 2 (fraction 20) from PMA-induced U937 cells, we 
obtained two unambiguous amino acid sequences: a major 
sequence, SVDPKNYPK, and a minor sequence, ALYGYAA. 
Sequencing of the corresponding peak (fraction 20) and of 
two adjacent fractions (nos. 19 and 21) from the uninduced 
U937 cells showed neither of these peptides. A search of nu- 
cleic acid and protein sequence data banks matched the major 
sequence, SVDPKNYPK, to the human IblB protein (100% 
homology) (22).  The yield of the peptide was 3.5 pmols, 
suggesting about 0.1% occupancy of the HLA class I binding 
sites by the IL-1/~ peptide. The HPLC elution characteristics 
of a synthetic peptide with the sequence SVDPKNYPK was 
determined using conditions identical to those under which 
the natural peptides were isolated.  Both synthetic and nat- 
ural peptides duted in the 20-21 rain range (data not shown). 
The IL-1B peptide shares with the CMV peptide a serine res- 
idue in the first position and a lysine residue in the 9th posi- 
tion, suggesting an allele-specific motif in the structure of 
Figure  5.  Expression of IIrl~ mRNA in differentiation-induced  and 
-uninduced  U937 cells. Total KNA was obtained from PMA-treated and 
untreated U937 ceils and reverse-transcribed into eDNA. The cDNAs were 
analyzed for the presence offl-actin and I~lfl message using specific  primers 
in the presence of  radiolabeled nudeotides in a PCR. Amplifications prod- 
ucts were analyzed by agarose gel electrophoresis and autoradiography. 
The autoradiogram  is from a 2-h exposure at room temperature.  (lane 
A). Ibl B primers  and control eDNA from LPS-treated  macrophages. 
(Lane  B)  IL-I~ primers,  uninduced  U937.  (Lane C)  Ibl~  primers, 
differentiation-induced U937. (Lane D) ~-actin primers, uninduced U937. 
(Lane E) B-actin primers,  differentiation-induced  U937. 
these HLA class I bound peptides. The yield of the FrH amino 
acid derivatives of the minor sequence (ALYGVAA) dropped 
below the level of  detection after the 7th cycle  of Edman degra- 
dation, preventing further analysis, and this peptide showed 
no sequence homology to any proteins contained in the data 
bases. 
The presence or absence of a given peptide, bound to MHC 
molecules, probably depends on the level of expression of the 
corresponding protein and gene. To determine whether the 
absence of the IL-13 peptide on uninduced U937 cells was 
due to quantitative differences in the level of II.-l~ expres- 
sion, we measured the amount of II.-l~/messenger RNA by 
quantitative reverse PCR. RNA was extracted from induced 
and uninduced U937, reverse transcribed,  and equal amounts 
of eDNA amplified in the presence  of appropriate primers 
and [3~pJdNTPs. Analysis of the amplified material showed 
that differentiated U937 cells strongly expressed IL-1B  mRNA. 
Uninduced cells, however, expressed at least 50 times less of 
this message  (Fig.  5). 
Peak  3  of both PMA-treated and untreated U937  cells 
yidded an identical peptide which could not be matched to 
a precursor. 
Peak 4 of PMA-treated U937 yielded a peptide whose se- 
quence was XIXKVGNQK.  The corresponding peak from 
non PMA-treated U937 contained a peptide with a different 
sequence: AVPASXKV.  Neither of these two peptides matched 
known sequences. 
Discussion 
The recent development of methods for analyzing endog- 
enous MHC bound peptides from cell lines  or tissues, by 
HPLC profiles and amino acid sequence analysis of individual 
peptides, allows the characterization of transformation and 
differentiation-specific  peptides bound to MHC molecules. 
Such studies are central to our understanding of the ability 
of the immune  response to discriminate between self and non- 
sdf antigens and may permit the identification of neoantigens 
associated with malignant transformation. 
In this report we describe for the first time an endogenously 
processed differentiation-stage specific peptide derived from 
a cytokine bound to MHC class I molecules. 
The human monoblastoid  leukemia cell line U937 is a model 
in which differentiation of precursor ceils can be studied. After 
PMA treatment, U937 ceils undergo morphological and func- 
tional changes which result in the acquisition of a macrophage- 
like phenotype. We have compared the HPLC profile and the 
sequence of prominent peaks of HLA class I associated pep- 
tides duted from PMA-treated and untreated U937 calls. 
One of the self peptides identified appears to derive from 
II.-l~/. Ibl~ is a cytokine with a wide variety of effects on 
cells involved in inflammation, immune responses,  and he- 
matopoiesis. Although IL-lfl is predominantly secreted by 
activated  monocytes/macrophages, a great variety of other 
cells, including endothelial, dendritic, smooth muscle, etc., 
have also been shown to secrete IL-lfl (23). 1L-lfl is unusual 
among most secreted proteins in that the II..lfl precursor pro- 
tein lacks the typical signal sequence which directs vectorial 
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ripheral blood monocytes, II-1/3 is synthesized as a 35-kD 
precursor  protein.  Upon  activation  with  LPS,  I1-1/3 is 
processed in the cytoplasm to its biologically active 17-kD 
form and secreted via a brefeldin A and monensin (inhibitors 
of vesicular traffic at the ER and Golgi level, respectively) 
insensitive pathway (25). 11-1/3 biosynthesis in PMA-induced 
U937 cells appears to be similar to that in peripheral blood 
monocytes. IIA3 is not detectable in supernatants from U937 
control cells, whether assayed by bioactivity or RIA (26). 
Northern blot analysis also demonstratesthat Ibl/5 messenger 
RNA is not present in U937 control cells that have not been 
treated with PMA. 48 h after (PMA) induction, however, 
I1-1/3 message becomes detectable  and increases up to 16 d 
thereafter (27).  Western blot analyses of I1-1/3 protein ex- 
pression in PMA-treated U937 cell lysates and culture super- 
natants show the accumulation of large amounts of the 35-kD 
precursor protein within the cells and its secretion into the 
extracellular compartment (25). Culture supernatants also con- 
tain the 17-kD form of 11.,1/3 (25). 
Our results corroborate these studies by demonstrating that 
uninduced U937 cells express a minimal amount IL-1/3  mRNA 
and that differentiation-induction affects an increase in I1-1/3 
mRNA expression.  That an increase in I1-1/3 mRNA ex- 
pression is accompanied by the appearance of the I1-1/3 pep- 
tide bound to MHC molecules, suggests that the de novo 
transcription of differentiation-stage specific genes can result 
in the presentation of the corresponding peptides by MHC 
molecules. 
The finding that an I1-1/3-derived peptide binds to MHC 
class I molecules is consistent with the current view on MHC 
class I antigen presentation of endogenously processed pro- 
teins (28). The 11-1/3 peptide sequence, S  ~  VDPKNYPK  ~s, 
is contained within the biologically active 17-kD form of IL-1/3 
(AllT-S  269) adjacent to two lysine residues, which have been 
identified as potential proteolytic cleavage sites (24), suggesting 
that a tryptic protease  is involved in its processing.  Since 
differentiation induction by PMA results  in the accumula- 
tion of a cytoplasmic pool of I1-1/3 precursor protein within 
U937 cells, our data suggest that this protein becomes acces- 
sible to proteosomes and transport associated proteins, and 
enters the endogenous pathway of antigen presentation. These 
processing events may account for the formation of an I1-13 
peptide-MHC class I complex. 
The fact that developmentally  regulated self proteins, such 
as receptors (29-31) and cytokines are processed and presented 
by MHC molecules provides important clues about the way 
in which the TCR repertoire is shaped. It is apparent that, 
to avoid autoimmunity, TCR reacting with cytokine and 
cytokine receptor-peptides should be subjected  to deletion 
during intrathymic development and that such deletion re- 
quires recognition of the corresponding peptides on self MHC. 
This hypothesis is substantiated by the present observation 
that an IL-1/3-derived peptide binds to MHC class I mole- 
cules, and by previous studies showing that peptides derived 
from the transferrin receptor (29) as well as MHC proteins 
(29-31) can bind to MHC class II molecules. In situ hybrid- 
ization studies, which have revealed the intrathymic expres- 
sion of II,-13 at the junction between the cortex and the 
medulla, support the concept that I1-1B-specific TCR can 
be deleted within the thymus (32). 
While the I1-1/3 peptide was displayed only by the HLA 
molecules of induced U937 cells, a peptide derived from a 
CMV structural protein was found on both induced and unin- 
dueed U937 cells. Given the absence of inclusion bodies in 
U937 cells, this finding was unexpected. However,  the fact 
tha~ U937 cells are infected with CMV was substantiated 
by PCR analysis of U937 eDNA using a CMV-specific probe 
for the IE antigen (Harris, P., unpublished results). The rela- 
tive amount of CMV structural peptide was greater in PMA- 
treated cells. This is consistent with the observation that 
differentiation-induction of U937 removes an early block to 
herpes simplex virus 1 replication (33). 
The CMV peptide which we found matches the data base 
sequence at seven out of nine residues. Since human CMV 
is a heterogeneous family, comprising thousands of strains 
that can be identified by restriction mapping analysis (34), 
the peptide sequence obtained is probably derived from an 
uncharacterized strain.  Our data are reminiscent of those 
reported by Rudensky et al. (31) who found peptides derived 
from the envelope protein gp70 of murine leukemia virus 
AKV and/or Pad LV bound to MHC class II molecules (I- 
A  b, I-Eb). PCR analysis of cDNA derived total mRNA of 
the murine cell line confirmed the fact that the line contained 
a latent viral infection, as is also the case of U937 grown 
in our laboratory. Lastly, although structural similarity exists 
between the I1-13 and CMV peptides and the I1-1/3 and CMV 
precursor proteins, respectively, it is not excluded that these 
MHC  bound peptides derive  from other uncharacterized 
precursors. 
The characterization  of differentiation-stage specific pep- 
tides should further our understanding of the molecular basis 
of self-non-self discrimination. Malignant transformation is 
presumably accompanied by alteration in the antigenic profile 
of MHC bound peptides. It is expected that such cells may 
acquire the expression of neoantigens, while also losing the 
capacity to present peptides corresponding to proteins that 
they cease producing. The identification of these peptides and 
other MHC bound self peptides from cells at different stages 
of differentiation remains a challenge for the future. 
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